Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies
Once a patient’s RAS status is known, does this inform the sequence of therapies? How can RAS testing be used to inform later lines of treatment?
In the U.S., the majority of patients receive EGFR antibodies after first line. To be clear, it's perfectly reasonable to give either bevacizumab or an EGFR antibody to patients in the frontline setting if they have a RAS wild type tumor. The practice in the U.S. has historically been to defer EGFR antibodies to later lines. Not that there's evidence that you should do it, it's just that it has been the practice. As such, all RAS testing is best done early in treatment so when you arrive at the point where you need to make a decision where there might be progression, you have in your hands to tell you whether a patient can or should receive an EGFR antibody.
Unresectable Colon Cancer: Case 2
52-year-old woman newly diagnosed with metastatic CRC and is genotyped as part of her initial work up.
Sotorasib/Panitumumab Combo Improves PFS in Refractory KRAS G12C+ mCRC
October 23rd 2023The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
T-IELs Could Hold the Key for CRC Immunotherapy
October 10th 2023Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
Read More
CAPOX Regimen Appears Noninferior to FOLFOX in CRC
October 8th 2023The treatment landscape for patients with resected stage III colon cancer has undergone a significant change, following publication of an International Development and Education Award presentation abstract in the August 2023 Journal of the National Comprehensive Cancer Network.
Read More
